Addex Therapeutics Ltd
ADDXF
Other OTC0.99
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.84
3Y
- -
77.03
5Y
- -
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Timothy Mark Dyer
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Chemin des Mines, 9 Geneva Switzerland 1202
- IPO Date
- Oct 15, 2010
- Website
- addextherapeutics.com
- Similar Companies
- Business
- Addex Therapeutics Ltd Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule allosteric modulators for neurological and neuropsychiatric disorders. The company develops therapies targeting metabotropic glutamate receptors (mGlu) and gamma-aminobutyric acid receptor B (GABAB), including its lead candidate dipraglurant, an mGlu5 negative allosteric modulator (NAM) under evaluation for brain injury recovery such as post-stroke and traumatic brain injury; ADX71149, an mGlu2 positive allosteric modulator (PAM) previously partnered with Janssen Pharmaceuticals that Addex regained rights to in 2025 for potential advancement in schizophrenia and anxious depression; an independent GABAB PAM program for chronic cough, which demonstrated robust anti-tussive activity in preclinical models; and earlier-stage preclinical candidates such as mGlu7 NAM for post-traumatic stress disorder and mood disorders, mGlu4 PAM for Parkinson's disease, mGlu2 NAM for mild neurocognitive disorders, and M4 PAM for schizophrenia through its 20% equity stake in spin-out Neurosterix LLC. Addex Therapeutics Ltd maintains ongoing partnerships, including with Indivior PLC, which advanced a GABAB PAM candidate through IND-enabling studies for substance use disorders in 2025, and entered an option agreement with Sinntaxis in 2025 for intellectual property covering mGlu5 NAM use in brain injury recovery. The company launched Neurosterix as a spin-out in 2024 with CHF5 million in cash proceeds and a 20% equity interest, divested non-core assets to extend its financial runway, and led a financing round in Stalicla for precision medicine in neurodevelopmental disorders; it was founded in 2002, formerly known as Addex Pharmaceuticals Ltd, and is headquartered in Geneva, Switzerland, with subsidiaries in France and the United States, while its shares trade on the SIX Swiss Exchange and Nasdaq Capital Market under the ticker ADXN.
Zymeworks (NASDAQ:ZYME) and Addex Therapeutics (OTCMKTS:ADDXF) Head to Head Survey